The global efforts to improve CAR T-cell therapy


Within the global efforts to improve CAR T-cell therapy, presentations revolved around engineering of CAR-T, including  next-generation CAR T-cells to overcome resistance,  improved CAR-T approaches to lymphoid malignancies, targeted genomic insertion, virus-free gene transfer and genome editing, and adaptor/uni-CARs). Current CAR-T trial activities in China were also reviewed.

Click on the titles below to read more and view the presentations (if available).

Keynote lecture: Improved CAR T-cell approaches for lymphoid malignancies (Martin Pule, UK)

Keynote Lecture: Updates in CAR T-cell therapy (Carl June, USA)

ROR1 CAR T-cell therapy in CLL and solid tumors (Jennifer Specht, USA)

Liso-cel pivotal TRANSCEND data (Jeremy Abramson, USA)

Visualizing CAR T-cells at work (Johannes Huppa, Austria)

Keynote Lecture: Current CAR-T trial activities in China (Jianxiang Wang, China)